Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Effects of dutasteride on lower urinary tract symptoms and general health in men with benign prostatic hypertroplasia and hypogonadism: a prospective study.

Shigehara K, Koh E, Sakamoto J, Yaegashi H, Izumi K, Ueno S, Kitagawa Y, Maeda Y, Kadono Y, Konaka H, Mizokami A, Nakashima T, Namiki M.

Aging Male. 2014 Mar;17(1):51-6. doi: 10.3109/13685538.2013.845744. Epub 2013 Oct 17.

PMID:
24134649
3.

Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study.

Wada N, Kita M, Hashizume K, Matsumoto S, Kakizaki H.

Neurourol Urodyn. 2013 Nov;32(8):1123-7. doi: 10.1002/nau.22349. Epub 2013 Jul 17.

PMID:
23861329
4.

[Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker : its effect on overactive bladder].

Wada N, Hashidume K, Tamaki G, Kita M, Iwata T, Matsumoto S, Kakizaki H.

Hinyokika Kiyo. 2012 Sep;58(9):475-80. Japanese.

5.

Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.

Araki K, Naya Y, Inahara M, Suzuki F, Ota S, Tsuji H, Mikami K, Yanagisawa M, Awa Y, Suzuki H.

Int J Urol. 2014 Aug;21(8):815-9. doi: 10.1111/iju.12459. Epub 2014 Apr 15.

6.
7.

Effects of dutasteride on lower urinary tract symptoms: a prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction.

Shigehara K, Miyagi T, Nakashima T, Izumi K, Kitagawa Y, Mizokami A, Koh E, Shimamura M, Namiki M.

Aging Male. 2016 Jun;19(2):128-33. doi: 10.3109/13685538.2016.1145205. Epub 2016 Feb 18.

PMID:
26890877
8.

Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.

O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K.

BJU Int. 2003 Aug;92(3):262-6.

9.

Dutasteride improves bone mineral density in male patients with lower urinary tract symptoms and prostatic enlargement: a preliminary study.

Wada N, Hashizume K, Matsumoto S, Kakizaki H.

Aging Male. 2016;19(1):12-4. doi: 10.3109/13685538.2015.1072155. Epub 2015 Jul 30.

PMID:
26225793
10.
12.

Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.

Page ST, Hirano L, Gilchriest J, Dighe M, Amory JK, Marck BT, Matsumoto AM.

J Urol. 2011 Jul;186(1):191-7. doi: 10.1016/j.juro.2011.03.026. Epub 2011 May 14.

13.

Safety and efficacy of 8-mg once-daily vs 4-mg twice-daily silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (SILVER Study): a 12-week, double-blind, randomized, parallel, multicenter study.

Choo MS, Song M, Kim JH, Lee KS, Kim JC, Kim SW, Yang SK, Lee JG, Lee JZ, Kim DK, Park WH, Kim KD, Na YG, Kwon DD, Paick JS.

Urology. 2014 Apr;83(4):875-81. doi: 10.1016/j.urology.2013.11.013. Epub 2014 Feb 12.

PMID:
24529580
14.

Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.

Wada N, Matsumoto S, Kita M, Hashizume K, Kakizaki H.

Int J Urol. 2014 Dec;21(12):1258-62. doi: 10.1111/iju.12570. Epub 2014 Jul 15.

15.

Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.

Casabé A, Roehrborn CG, Da Pozzo LF, Zepeda S, Henderson RJ, Sorsaburu S, Henneges C, Wong DG, Viktrup L.

J Urol. 2014 Mar;191(3):727-33. doi: 10.1016/j.juro.2013.09.059. Epub 2013 Oct 2.

PMID:
24096118
16.

Dutasteride in men receiving testosterone therapy: a randomised, double-blind study.

Kacker R, Harisaran V, Given L, Miner M, Rittmaster R, Morgentaler A.

Andrologia. 2015 Mar;47(2):148-52. doi: 10.1111/and.12237. Epub 2014 Feb 6.

PMID:
24499051
17.

The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.

Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F; CombAT Study Group.

Eur Urol. 2009 Feb;55(2):461-71. doi: 10.1016/j.eururo.2008.10.037. Epub 2008 Nov 6.

PMID:
19013011
18.

Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.

Marberger M, Roehrborn CG, Marks LS, Wilson T, Rittmaster RS.

J Clin Endocrinol Metab. 2006 Apr;91(4):1323-8. Epub 2006 Jan 24.

PMID:
16434455
19.

Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.

Gittelman M, Ramsdell J, Young J, McNicholas T.

J Urol. 2006 Sep;176(3):1045-50; discussion 1050.

PMID:
16890688
20.

Comparison of alfuzosin 10 mg with or without propiverine 10 mg, 20 mg in men with lower urinary tract symptom and an overactive bladder: randomised, single-blind, prospective study.

Cho HJ, Shin SC, Seo DY, Cho JM, Kang JY, Yoo TK, Yu JH, Sung LH, Moon HS.

Int J Clin Pract. 2014 Apr;68(4):471-7. doi: 10.1111/ijcp.12339. Epub 2014 Jan 29.

PMID:
24471868

Supplemental Content

Support Center